Table 3.

Biological pathways targeted by the 7 primary endpoint-associated miRNAs in the HOPE trial^a,b

Pathway Name	HOPE p-value	Ratio genes/pathway	# genes in dataset	# in IPA pathway	Genes within Respective Pathway
Estrogen mediated S-phase entry	0.003	0.38	9	24	RB1, CCNE1, E2F1, CDKN1A, E2F5, E2F3, CCND1, ESR1, E2F2
P53 signaling	0.006	0.16	18	111	PMAIP1, TP63, TNFRSF10B, PERP, BAX, CCND1, PTEN, BCL2, CCNG1, RB1, RHOV, CCNE1, NF1, IRS1, E2F1, SIRT1, AKT3, PIK3R2
Glioblastoma multiform signaling	0.011	0.13	21	158	TSC1, RHOC, CDK6, WNT16, RHOJ, E2F3, CCND1, PDGFB, PTEN, PLCD1, RB1, RHOV, CCNE1, NF1, IRS1, E2F1, CDKN1A, E2F5, AKT3, PIK3R2, E2F2
Cell cycle: G 1/S Checkpoint regulation	0.013	0.19	12	63	RB1, RBL2, CCNE1, MAX, HDAC8, E2F1, CDKN1A, E2F5, CDK6, E2F3, CCND1, E2F2
Molecular mechanisms of cancer	0.015	0.10	36	368	JAK1, BMPR2, WNT16, E2F3, MAPK11, CCND1, BCL2, TGFBR2, RB1, E2F5, AKT3, PRKCE, PIK3R2, E2F2, PMAIP1, RHOC, CDK6, RHOJ, BAX, BAK1, GNAI3, CCNE1, RHOV, MAX, MAPK14, CBL, RABIF, NF1, IRS1, CDKN1A, E2F1, PAK5, BMP7, BCL2L11, PSEN1, PRKCB
Glioma signaling	0.017	0.15	16	109	RBL2, CDK6, E2F3, CCND1, PDGFB, PTEN, RB1, IRS1, E2F1, CDKN1A, E2F5, AKT3, PRKCE, PIK3R2, E2F2, PRKCB
Chronic Myeloid Leukemia Signaling	0.022	0.15	15	103	TGFBR2, RB1, RBL2, HDAC8, IRS1, CRKL, E2F1, CDKN1A, E2F5, CDK6, AKT3, PIK3R2, E2F3, CCND1, E2F2
Role of JAK family kinases in IL 6-type Cytokine signaling	0.022	0.28	7	25	JAK1, MAPK14, OSM, OSMR, STAT3, IL6, MAPK11
Pancreatic adenocarcinoma signaling	0.025	0.14	16	118	JAK1, STAT3, E2F3, CCND1, BCL2, TGFBR2, VEGFA, RB1, CCNE1, IRS1, E2F1, CDKN1A, E2F5, AKT3, PIK3R2, E2F2
Cell cycle regulation by BTG family proteins	0.027	0.23	8	35	RB1, CCNE1, E2F1, E2F5, BTG1, E2F3, CCND1, E2F2

Pathway analyses created using Ingenuity Pathway Analysis software (Qiagen, Inc.)

Abbreviations: HOPE: Hormones and Physical Exercise

^amiR_93_5p has the same ‘seed’ sequence as miR_17_5p and thus is a predictive duplicate

^bp value <0.05 considered significant